Compare ADMA Biologics Inc (ADMA) vs Bank of Nova Scotia (BNS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Bank of Nova Scotia — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while Bank of Nova Scotia trades at $84.92 (market cap $105.63B). The key difference: Bank of Nova Scotia is far larger — about 49.6× ADMA Biologics Inc's market cap, and Bank of Nova Scotia pays a 3.83% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | BNS | |
|---|---|---|
Market Cap | $2.13B | $105.63B |
Sector | Health | Financials |
52-Week High | $20.38 | $87.35 |
52-Week Low | $7.60 | $54.50 |
Enterprise Value | $2.20B | — |
Dividend Yield | — | 3.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
BNS trades at $86.20, up 0.94% today, with strong technical momentum showing bullish moving averages and resistance near $88. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS expected at $1.51, while revenue grew to $37.10B in 2025. Recent news highlights dividend increases and strategic acquisitions like MapleMark Bank, reinforcing growth prospects in global markets.
Outlook remains positive with analyst consensus favoring Buy ratings (52.63%), though valuation multiples like P/E of 17.05 warrant monitoring. Key risks include economic sensitivity and debt levels, but robust cash flow and dividend yield support income-focused investors. Upside depends on execution of growth initiatives and sustained earnings momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Bank of Nova Scotia
Bank of Nova Scotia is a global financial services provider. The bank has five business segments: Canadian banking, international banking, global wealth management, global banking and markets, and other. It offers a range of advice, products, and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. The bank's international operations span numerous countries and are more concentrated in Central and South America.
Read more on BNS →
